Brent Meadows

Chief Business Officer Senovia Biosciences

A seasoned biotech business development and commercialization leader, he brings over 20 years of experience across global marketing, product launches, licensing, due diligence and commercial operations. He has led multiple successful in- and out-licensing transactions spanning oncology, neuroscience and rare disease, including partnerships involving J&J, AVEO Oncology and Precision Biosciences. His expertise includes strategic alliances, portfolio optimization, P&L management, clinical development planning and KOL engagement, with a strong track record of translating emerging opportunities into actionable growth strategies.

Seminars

Thursday 3rd December 2026
Horizon Scanning Roundtable: Where Could Amylin Biology Create Value Beyond Metabolic Disease?
11:30 am
  • Investigating amylin's potential in type 1 diabetes for glycemic control and hypoglycemia reduction
  • Examining metabolic benefits for MASH, kidney disease, and cardiovascular outcomes
  • Discussing speculative but intriguing indications: addiction, alcohol use disorder, sleep disorders, and Alzheimer's disease
Headshot of Brent Meadows, Chief Business Officer at Senovia Biosciences, at the Amylin-Based Therapeutics Summit